Navigation Links
FDA Approves Agriflu Seasonal Influenza Vaccine
Date:11/27/2009

Another option to prevent illnesses caused by subtypes A and B influenza virus

SILVER SPRING, Md., Nov. 27 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Agriflu, manufactured by Novartis Vaccines and Diagnostics in Siena, Italy, was approved using the FDA's accelerated approval pathway, which helps safe and effective medical products for serious or life-threatening diseases become available sooner. In this case, Novartis demonstrated that the vaccine induced levels of antibodies in the blood likely to be effective in preventing seasonal influenza.

Agriflu is administered as a single injection in the upper arm and is available in single dose, pre-filled syringes that do not contain preservatives.

"The approval of the new seasonal influenza vaccine, Agriflu, is an important step in adding to the production capacity to enhance the supply of vaccine for the United States for future influenza seasons," said Karen Midthun, M.D., acting director of the FDA's Center for Biologics Evaluation and Research.

Common side effects in clinical studies included pain, swelling and redness at the injection site, headache, muscle aches and malaise. People with severe or life-threatening allergies to chicken eggs, or to any other substance in the vaccine, should not be vaccinated.

As part of the accelerated approval process, Novartis is required to conduct further studies to verify that the vaccine induces levels of antibodies in the blood that are effective in preventing seasonal influenza. The company also manufactures another licensed seasonal influenza vaccine, Fluvirin, for use in the United States. Fluvirin is approved for people ages 4 years and older. Agriflu is not intended to protect against the 2009 H1N1 influenza.

For more information, visit FDA's Webpage on 2009 - 2010 Season Flu Vaccines at:

http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm100139.htm

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lysteda to Treat Heavy Menstrual Bleeding
2. Rogan-Delft Approves Matrox Xenia Series for Use With Zillion Suite
3. FDA approves GlaxoSmithKlines VOTRIENT(TM) for advanced renal cell cancer
4. FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric Use
5. FDA Approves New Treatment for Advanced Form of Kidney Cancer
6. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
7. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
8. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
9. Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
10. FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
11. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)...  Amy Baxter MD, chief executive officer and founder ... relief, was awarded a 2017 Top 40 Healthcare Transformer ... at the MM&M Top 40 Healthcare Transformers dinner and ... on May 10, 2017. The dinner followed a full-day ... the pill."  "Innovation goes beyond invention," noted ...
(Date:5/10/2017)... 2017 Hologic, Inc. (Nasdaq: HOLX ... fiscal second quarter ended April 1, 2017 .   ... 666.7% compared to the prior year period as the ... significant gain, while non-GAAP diluted EPS of $0.50 increased ... in constant currency terms.  Excluding the effects of blood ...
(Date:5/10/2017)... GLEN BURNIE, Md. , May 10, 2017 /PRNewswire/ ... and retention solutions for the clinical research industry, is ... website, www.CSSiEnroll.com . The new website features both ... better overall user experience and enhances the company,s already ... in the industry. "After many months ...
Breaking Medicine Technology:
(Date:5/23/2017)... , ... May 23, 2017 , ... ... receive treatment using the SPEED System™ Orthodontics, with or without a referral, from ... in El Segundo, CA, who is skilled in providing patients with the ...
(Date:5/22/2017)... NY (PRWEB) , ... May 22, 2017 , ... Patients ... urged to receive relaxing sedation dentistry in Mt. Kisco, NY from Advanced Endodontics of ... administered for a variety of treatments. One or more sedation methods may be recommended ...
(Date:5/22/2017)... ... May 22, 2017 , ... “Homeostasis: The Journey of a ... live with Bipolar 1. Donald Rodriguez takes readers on a rollercoaster ride that includes ... dead of winter and to a dark place where Donald considers suicide. Readers ...
(Date:5/22/2017)... ... May 22, 2017 , ... OSF Ventures, the corporate investment ... an early stage company in San Francisco that has developed software to individualize ... Innovation Fund acted as the lead investor in the round. , Medicine ...
(Date:5/21/2017)... ... May 20, 2017 , ... Pixel Film Studios presents a ... in Final Cut Pro X. The business-oriented elements and dignified animations are designed ... Corporate will deliver a professional and distinguished look to any multi-line text animation ...
Breaking Medicine News(10 mins):